Novel mRNA vaccine plus immunotherapy reduces melanoma relapse in phase 3 trial
Posted:
In 2022, about 330,000 people around the world were diagnosed with the skin cancer melanoma, with about 60,000 people dying from the condition.
On August 19, pharmaceutical companies Merck and Moderna announced the phase 3 clinical study results for an experimental therapy designed to help lower the recurrence rate in people with stage IIB-IV melanoma who have had their tumor completely removed.
The VPodDuoss (the ‘V’ stands for virus)— can read and compare results from a variety of tests for pathogens or cancer-associated biomarkers.
It’s the brainchild of Lee, University of Illinois Urbana-Champaign Computer Engineering Professor Brian Cunningham, PhD, and Bioengineering Professor Xing Wang, PhD,…
Atherosclerosis, the process underlying most cardiovascular diseases, begins long before the first symptoms appear.
An international study led by Professor Henning Bundgaard, Professor of Cardiology at Rigshospitalet in Copenhagen, Denmark, and Dr Borja Ibáñez, Scientific Director of the Centro Nacional…
Attendees
Sponsors and Exhibitors
Contact us